FDA clears Park’s MCAT system

March 19, 1997

Park Medical Systems of Lachine, Quebec, has received the Foodand Drug Administration's go-ahead to market its Molecular CodedAperture Technology (MCAT), a collimator-based method for improvinggamma camera imaging at all energy levels.MCAT consists of

Park Medical Systems of Lachine, Quebec, has received the Foodand Drug Administration's go-ahead to market its Molecular CodedAperture Technology (MCAT), a collimator-based method for improvinggamma camera imaging at all energy levels.

MCAT consists of macro-collimators that attach to standard detectors,creating a coded pattern that is detected by the camera's photomultipliertube array. Software decodes the pattern into a high-resolutionimage covering a wide range of energies. Park believes the techniqueis more versatile than coincidence-detection methods for oncologyimaging.

Park will show the MCAT module, as well as clinical images, atthe Society of Nuclear Medicine meeting in San Antonio, TX, inJune.